CRDF Stock Analysis: Buy, Sell, or Hold?
CRDF - Cardiff Oncology, Inc. Common Stock
$1.75
0.14 (8.36%)
▲
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
25d
Get Alerted When CRDF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called CRDF this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CRDF is down 39.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CRDF is down 39.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CRDF is currently trading at $1.75, which is considered oversold relative to its 30-day fair value range of $2.31 to $3.20.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.58, while resistance sits at $3.05. The stock is showing strong short-term momentum, up 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+519.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.58, while resistance sits at $3.05. The stock is showing strong short-term momentum, up 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+519.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.31 -
$3.20
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
Protect Your Profits
Holding CRDF? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.4%)
- BULLISH: Trading 519.2% below Wall St target ($10.00)
- WARNING: Recommendation downgraded due to -39.7% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.31 -
$3.20
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.58
Resistance Level
$3.05
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.10
Wall Street Target
$10.00
(+519.2%)
Revenue Growth (YoY)
-27.3%
Last updated: January 31, 2026 3:54 AM ET
Data refreshes hourly during market hours. Next update: 4:54 AM
Data refreshes hourly during market hours. Next update: 4:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$486 | 45 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$214 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$273 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$19 | 55 HOLD |
Advanced CRDF Option Strategies
Professional options setups generated by AI based on today's CRDF price and gamma walls.
